PUBLISHER: The Business Research Company | PRODUCT CODE: 1391047
PUBLISHER: The Business Research Company | PRODUCT CODE: 1391047
“Bleeding Disorders Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on bleeding disorders treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for bleeding disorders treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The bleeding disorders treatment market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Bleeding disorders constitute a category of medical conditions characterized by inadequate blood clotting, leading to prolonged bleeding following surgery, injury, menstruation, or trauma. The management of these disorders aims to either arrest or diminish the frequency of bleeding episodes.
Key modalities in the treatment of bleeding disorders encompass desmopressin (DDAVP), hormone replacement therapy, contraceptives, anti-fibrinolytic or clot-stabilizing medications, fibrin sealants, drugs for topical application on cuts, and pipeline analysis. Desmopressin (DDAVP) therapies play a pivotal role in diagnosing individuals with mild hemophilia A or von Willebrand disease, effectively halting bleeding. Targeted diseases include hemophilia A, hemophilia B, von Willebrand disease, liver disease, and others. These interventions cater to diverse end users, including hospitals, clinics, specialty clinics, research institutes, and related entities.
The bleeding disorders treatment market research report is one of a series of new reports from The Business Research Company that provides Bleeding disorders treatment market statistics, including bleeding disorders treatment industry global market size, regional shares, competitors with bleeding disorders treatment market share, detailed Bleeding disorders treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the bleeding disorders treatment industry. This bleeding disorders treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The bleeding disorders treatment market size has grown strongly in recent years. It will grow from $15.37 billion in 2023 to $16.84 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. The growth observed during the historical period can be ascribed to heightened patient awareness, improved healthcare accessibility, advancements in hemophilia therapies, and the expansion of the global market.
The bleeding disorders treatment market size is expected to see strong growth in the next few years. It will grow to $23.71 billion in 2028 at a compound annual growth rate (CAGR) of 8.9%. The anticipated growth in the forecast period is linked to factors such as an aging population, the emergence of personalized medicine, increased patient advocacy and support, a rise in disposable income, and an upswing in healthcare expenditure. Noteworthy trends expected during this period encompass the implementation of personalized treatment plans, the expansion of telehealth services, advancements in clotting factor therapies, the adoption of RNA-based treatments, and enhanced access to orphan drug designation.
The growth of the bleeding disorders treatment market is anticipated to be propelled by the increasing number of diagnosed hemophilia patients. Hemophilia, an inherited bleeding disorder characterized by inadequate blood clotting, necessitates replacement therapy for treatment. This involves replacing the deficient blood clotting factors with human plasma concentrates or recombinant forms of clotting factors VIII or IX. In 2021, the World Federation of Hemophilia reported nearly 234,000 confirmed cases of hemophilia worldwide. The escalating number of diagnosed hemophilia patients is a significant driver behind the growth of the bleeding disorders treatment market, emphasizing the importance of advancing treatments for this inherited disorder.
The expansion of the bleeding disorders treatment market is expected to be driven by the rising healthcare expenditure. Healthcare expenditure encompasses spending on healthcare-related goods and services within a given healthcare system or economy. In November 2022, the Canadian Institute for Health Information reported a notable increase in healthcare expenditure, reaching 0.8%, equivalent to $331 billion in 2022, compared to 7.6% in 2021. This heightened healthcare expenditure is crucial in supporting the development and accessibility of bleeding disorders treatments. The growing financial commitment to healthcare services reflects a broader trend contributing to the expansion of the bleeding disorders treatment market.
A key trend gaining prominence in the bleeding disorder treatment market is technological advancements. Major companies operating in this sector are actively focusing on developing innovative technologies to maintain their market positions. An illustrative example is the University of Oslo, which, in 2021, introduced a groundbreaking technology called super albumin. This technology holds the potential to facilitate the development of long-acting medications, particularly benefiting individuals with hemophilia. The University's research team leveraged their understanding of a biological mechanism to create super albumin, a protein variant that, when combined with protein-based medications, extends their bloodstream half-life. This technological advancement represents a significant stride toward enhancing treatment options and outcomes in the bleeding disorders treatment market.
Leading companies in the bleeding disorder treatment market are actively developing on-demand treatments to control bleeding episodes and perioperative management solutions, addressing a broader customer base and aiming to boost sales and revenue. On-demand treatment is a crucial aspect of managing bleeding disorders, empowering individuals to respond promptly to bleeding episodes and ensuring safe perioperative care during surgical procedures. Ongoing advances in clotting factor therapies and treatment strategies are enhancing the overall quality of life for individuals with bleeding disorders, enabling them to lead more active and fulfilling lives. In February 2023, the collaboration between Sanofi and Sobi resulted in the development of the first-in-class, high-sustained factor VIII replacement therapy known as ALTUVIIIO, which received U.S. FDA approval. This groundbreaking medication offers a unique once-a-week dosing schedule, producing factor activity levels above 40% for the majority of the week and significantly reducing bleeding compared to previous factor VIII prophylaxis.
In October 2022, Pfizer Inc., a prominent U.S.-based pharmaceutical and biotechnology corporation, made a strategic move by acquiring Global Blood Therapeutics, Inc. (GBT) for an undisclosed amount. This acquisition was geared towards leveraging GBT's portfolio to expedite discovery processes and provide a range of potential best-in-class medicines for patients with sickle cell disease. Global Blood Therapeutics, Inc., a U.S.-based biopharmaceutical company specializing in the treatment of blood disorders, contributed valuable expertise and products to Pfizer's portfolio, aligning with the broader industry trend of strategic acquisitions to strengthen capabilities and enhance the range of therapeutic offerings in the bleeding disorder treatment market.
Major companies operating in the bleeding disorders treatment market include AbbVie Inc., Bayer AG, Novo Nordisk A/S, Pfizer Inc., Biogen Inc., CSL Behring Company, Grifols SA, Octapharma AG, BDI Pharma Inc., Ferring Pharmaceuticals Ltd., Xenetic Biosciences Inc., Sanofi SA, Alnylam Pharmaceuticals Inc., Novartis AG, Shire PLC, Novo Nordisk, Grifols SA, F. Hoffmann-La Roche AG, Sanofi Corporation, Takeda Pharmaceutical Company Limited, Kedrion S.p.A, Biotest AG, LFB S.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., HEMA Biologics LLC, ADMA Biologics Inc., Grifols Biologicals Inc., Octapharma Plasma Inc., Kedrion Biopharma Inc., BPL Plasma Inc., BioLife Plasma Services, CSL Plasma Ltd., Grifols Shared Services North America Inc., Octapharma USA Inc., Shire US Inc., Pfizer Canada Inc., Grifols Canada Ltd., Octapharma Canada Inc.
North America was the largest region in the bleeding disorders treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bleeding disorders treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the bleeding disorders treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The bleeding disorders treatment market includes revenues earned by entities by recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.